CagriSema 10 MG (Blend)

▎ Menene Semaglutid?

Semaglutid, a matsayin mai ɗaukar agonist mai karɓa na glucagon-kamar peptide-1 (GLP-1), an yi amfani dashi sosai a cikin maganin asibiti na nau'in ciwon sukari na 2. Ta hanyar kwaikwayon ayyukan ilimin lissafin jiki na GLP-1 na halitta, wannan magani yana haifar da ingantattun hanyoyin daidaita yanayin rayuwa bayan kunna mai karɓar GLP-1, gami da haɓaka haɓakar insulin-dogaran insulin, ƙa'idodin hanawa na sakin glucagon, jinkirin zubar da ciki, da babban tasirin hana ci abinci, ta haka ne ke samun nasarar daidaita matakan sarrafa glucose na jini. Kayan sa na musamman na pharmacokinetic yana ba shi rabin rayuwar har zuwa kwanaki 7, yana tallafawa tsarin allurar subcutaneous sau ɗaya mako-mako ko yanayin gudanar da baka na yau da kullun, wanda ke haɓaka ƙwarewar jiyya na marasa lafiya da haɓaka ƙimar magani.

Bayanan gwaji na asibiti sun nuna cewa semaglutide na iya rage girman haemoglobin glycated (HbA1c) da kusan 1.8%, kuma abubuwan da suka faru na hypoglycemic sun yi ƙasa sosai, wanda ke ba shi fa'ida ta musamman a cikin sarrafa glucose na jini. Bugu da ƙari, an tabbatar da tasirin kariya na zuciya da jijiyoyin jini na wannan miyagun ƙwayoyi, wanda zai iya rage haɗarin manyan cututtuka na zuciya da 26%, yana ba da ƙarin fa'idodin warkewa ga masu ciwon sukari da cututtukan zuciya. Baya ga maganin ciwon sukari, ana iya amfani da semaglutide don kula da kiba na dogon lokaci kuma ya nuna yuwuwar ƙimar warkewa a cikin bincike na asibiti akan cututtuka irin su steatohepatitis mara barasa da cutar Alzheimer.

Wannan tsarin jiyya da yawa wanda ya dogara da kunna mai karɓa na GLP-1 ba wai kawai yana haɓaka sigogi na rayuwa ba ta hanyar haɓaka haɓakar insulin, hana wuce kima na glucagon, da daidaita cibiyar ma'auni na makamashi ta tsakiya, amma kuma yana ba da ingantaccen dabarun jiyya don ingantaccen tsarin kula da cututtukan rayuwa na yau da kullun ta hanyar tasirin kariya na zuciya da jijiyoyin jini da fa'idodin tsarin juyayi na tsakiya. Ƙimar aikace-aikacen sa a cikin yankuna da yawa na cututtuka yana ƙara tabbatar da mahimmancin matsayi na GLP-1 agonists mai karɓa a matsayin hanyar jiyya ta asali a cikin maganin rayuwa na zamani.

▎ Takaitawa

Haɗin Cagrilintide da Semaglutid (Cagrisema) yana nuna mahimman tasirin haɗin gwiwa a cikin jiyya na kiba da nau'in ciwon sukari na 2. Wannan haɗin haɗin gwiwar yana samun ƙa'idodin abinci mai nau'i-nau'i, metabolism na glucose na jini, da sarrafa nauyi ta hanyar yin niyya a lokaci guda amylin da masu karɓar GLP-1. Cagrilintide yana daidaitawa ta hanyar jinkirta zubar da ciki da ka'idojin satiety na tsakiya, yayin da Semaglutid ya hana fitar da glucagon kuma yana haɓaka haɓakar insulin. Sakamakon synergistic na biyu yana haɓaka tasirin asarar nauyi da sarrafa glucose na jini.

Bayanan gwaji na asibiti sun nuna cewa Cagrisema (haɗin Cagrilintide 2.4mg da Semaglutid 2.4mg) yana haifar da asarar nauyi na 9.07% (cikakkiyar asarar nauyi na 9.11kg) a lokacin lokacin jiyya na 20 zuwa 32 makonni, wanda ya fi mahimmanci fiye da tsarin kulawa na yin amfani da Semaglutid 2.4mg sau ɗaya ^kawai . A cikin mako 32, multicenter, makafi biyu, gwaji na gwaji na lokaci na 2, asarar nauyi na marasa lafiya da aka bi da su tare da CagriSema ya fi girma fiye da na marasa lafiya da aka bi da su tare da Semaglutid ko Cagrilintide kadai. 

Rashin nauyi a cikin ƙungiyar CagriSema shine -15.6%, cewa a cikin ƙungiyar Semaglutid -5.1%, kuma a cikin ƙungiyar Cagrilintide shine -8.1% ^[2] . Bugu da ƙari, Cagrisema kuma yana aiki da kyau a cikin rage glycated haemoglobin (HbA1c) da inganta haɗarin cututtukan zuciya, yayin da haɗarin hypoglycemia ya yi ƙasa sosai. Ta hanyar tsarin manufa da yawa, wannan tsarin haɗin gwiwar ba wai kawai yana haɓaka sigogi na rayuwa ba har ma yana rage haɗarin abubuwan da ke faruwa na zuciya da jijiyoyin jini, yana ba da ƙarin zaɓi na jiyya ga marasa lafiya masu kiba da nau'in ciwon sukari na 2.

Game da Marubuci

Abubuwan da aka ambata a sama duk bincike ne, gyara su kuma Cocer Peptides ne suka haɗa su.

▎ Abubuwan da suka dace

[1] Dutta D, Nagendra L, Harish BG, et al. Inganci da Tsaro na Cagrilintide Kadai kuma a Haɗe tare da Semaglutid (Cagrisema) azaman Magungunan Kiba: Binciken Tsari da Meta-Analysis [J]. Jaridar Indiya ta Endocrinology da Metabolism, 2024,28:436-444.DOI:10.4103/ijem.ijem_45_24.

[2] Frias JP, Deenadayalan S, Erichsen L, et al. Inganci da aminci na cagrilintide sau ɗaya-mako-mako 2 · 4 MG tare da semaglutide sau ɗaya-mako-mako 2 · 4 MG a cikin nau'in ciwon sukari na 2: multicentre, bazuwar, makafi biyu, sarrafa aiki, gwajin lokaci na 2 [J]. Lancet, 2023,402 (10403):720-730.DOI:10.1016/S0140-6736(23)01163-7.

DUKKANIN LABARI DA BAYANIN KYAUTATAWA DA AKE BAYAR A WANNAN SHAFIN KAWAI DOMIN WATSA BAYANI NE DA MANUFOFIN ILIMI.  

Kayayyakin da aka bayar akan wannan gidan yanar gizon an yi niyya ne kawai don binciken in vitro. Binciken in vitro (Latin: *a cikin gilashi*, ma'ana a cikin gilashin gilashi) ana gudanar da shi a wajen jikin mutum. Waɗannan samfuran ba magunguna ba ne, Hukumar Abinci da Magunguna ta Amurka (FDA) ba ta amince da su ba, kuma dole ne a yi amfani da su don hanawa, magani, ko warkar da duk wani yanayi na likita, cuta, ko cuta. Doka ta haramta shigar da waɗannan samfuran cikin jikin mutum ko dabba ta kowace hanya.